MedTrace Logo

MS Fatigue and tDCS on Fatigue in Multiple Sclerosis

NCT05890885 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-01-22

No results posted yet for this study

Summary

The available therapeutic strategies for Multiple Sclerosis (MS)-related symptoms are usually faced with limited efficacy and numerous side effects. Patients with MS frequently suffer from fatigue, affective symptoms, and cognitive deficits.

Conditions

  • Fatigue in Multiple Sclerosis

Interventions

PROCEDURE

Real left prefrontal tDCS - sham

Real left prefrontal tDCS followed by sham tDCS after a 4-week washout period

PROCEDURE

Sham - Real left prefrontal tDCS

Sham tDCS followed by real left prefrontal tDCS after a 4-week washout period

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Samar AYACHE · Clinical Neurophysiology Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-04-20
Completion
2023-04-20

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05890885 on ClinicalTrials.gov